Evidence map›Paper›PMID 33406699›Full record

ArticleMolecules (Basel, Switzerland)2021

Concept Design, Development and Preliminary Physical and Chemical Characterization of Tamoxifen-Guided-Mesoporous Silica Nanoparticles.

Candace M Day, Martin J Sweetman, Shane M Hickey, Yunmei Song, Yongjun Liu, Na Zhang, Sally E Plush, Sanjay Garg

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Candace M DayClinical and Health Sciences, University of South Australia, North Terrace, Adelaide, SA 5000, Australia.
Martin J SweetmanClinical and Health Sciences, University of South Australia, North Terrace, Adelaide, SA 5000, Australia.ORCID 0000-0002-9074-2125
Shane M HickeyClinical and Health Sciences, University of South Australia, North Terrace, Adelaide, SA 5000, Australia.ORCID 0000-0002-3063-531X
Yunmei SongClinical and Health Sciences, University of South Australia, North Terrace, Adelaide, SA 5000, Australia.
Yongjun LiuSchool of Pharmaceutical Science, Shandong University, Ji'nan 250012, China.
Na ZhangSchool of Pharmaceutical Science, Shandong University, Ji'nan 250012, China.
Sally E PlushClinical and Health Sciences, University of South Australia, North Terrace, Adelaide, SA 5000, Australia.
Sanjay GargClinical and Health Sciences, University of South Australia, North Terrace, Adelaide, SA 5000, Australia.ORCID 0000-0001-7253-2629
University of South Australia · AUShandong University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Conventional chemotherapies used for breast cancer (BC) treatment are non-selective, attacking both healthy and cancerous cells. Therefore, new technologies that enhance drug efficacy and ameliorate the off-target toxic effects exhibited by currently used anticancer drugs are urgently needed. Here we report the design and synthesis of novel mesoporous silica nanoparticles (MSNs) equipped with the hormonal drug tamoxifen (TAM) to facilitate guidance towards estrogen receptors (ERs) which are upregulated in breast tumours. TAM is linked to the MSNs using a poly-ʟ-histidine (PLH) polymer as a pH-sensitive gatekeeper, to ensure efficient delivery of encapsulated materials within the pores. XRD, HR-TEM, DLS, SEM, FT-IR and BET techniques were used to confirm the successful fabrication of MSNs. The MSNs have a high surface area (>1000 m

Indexed as

Drug Delivery SystemsAntineoplastic Agents, HormonalBreast NeoplasmsDrug CarriersDrug CompoundingDrug DesignDrug DiscoveryDrug LiberationFemaleHumansNanoparticlesPorositySilicon DioxideTamoxifenAntineoplastic Agents, HormonalDrug CarriersSilicon DioxideTamoxifenbreast cancerfunctionalized nanostructuresmesoporous silica nanoparticlespoly-ʟ-histidinesurface reactivitytamoxifentargeting vector

Identifiers

PMID33406699
PMCPMC7795496
OpenAlexW3120915644

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.